What the Research Says About Safety Clinical studies on AOD9604 indicate that the peptide is generally welltolerated: In human trials, no significant adverse effects were reported at doses up to 1 mg/day (safety summary) Unlike growth hormone therapies, AOD9604 does not meaningfully elevate IGF1 levels (human data), which may reduce the risk of unwanted growthrelated side effects
Ipamorelin induces GH release with negligible effects on prolactin, ACTH, or ghrelin-mediated hunger making it ideal for targeted therapy. Bowers et al., Annals of the New York Academy of Sciences How to Use Ipamorelin (Dosing & Timing) Because of its short half-life and natural pulse-mimicking effect, Ipamorelin is most effective when used consistently and strategically
By completing a purchase, you verify that you are a qualified researcher and must comply with applicable local, state, and federal regulations
Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats
